Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Change in Accured Expenses (2016 - 2025)

Marimed (MRMD) has disclosed Change in Accured Expenses for 15 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 29.22% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.9 million, a 73.56% increase, with the full-year FY2024 number at $1.8 million, up 195.33% from a year prior.
  • Change in Accured Expenses was $1.3 million for Q3 2025 at Marimed, up from -$281000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.0 million in Q2 2021 to a low of -$8.8 million in Q4 2021.
  • A 5-year average of $84368.4 and a median of -$136000.0 in 2024 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 3223.55% in 2021; the steepest drop was 1011.6% in 2021.
  • Marimed's Change in Accured Expenses stood at -$8.8 million in 2021, then surged by 96.72% to -$289000.0 in 2022, then tumbled by 491.0% to -$1.7 million in 2023, then surged by 39.58% to -$1.0 million in 2024, then skyrocketed by 225.58% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Change in Accured Expenses are $1.3 million (Q3 2025), -$281000.0 (Q2 2025), and $1.9 million (Q1 2025).